Implementation Strategies for Monitoring Adherence in Real Time

Overview

The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: November 30, 2022

Detailed Description

Drawing from insights in behavioral economics and implementation science, the goal of our project is to identify effective strategies for improving lung cancer outcomes by helping patients to better manage symptoms and adhere to oral therapies. Given the rapid increase in FDA-approved targeted therapies, the need for such strategies will continue to grow. Our central hypothesis is that conversational agent will improve adherence to oral therapies by targeting patient-level determinants of behavior change. The specific aims are to: 1) Test the effects of a patient-directed intervention (conversational agent) to improve adherence to oral targeted therapies in patients with non-small cell lung cancer.; and 2) Use mixed-methods approaches with clinicians and patients to explore multilevel factors shaping the acceptability, effectiveness, and future implementation of intervention into routine cancer care. Primary trial outcomes (adherence and persistence) will be measured using microelectronic monitoring system (MEMS) caps. Secondary outcomes will be assessed using longitudinal surveys and medical record data.

Interventions

  • Device: Conversational Agent/Chatbot
    • Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients’ cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
  • Other: Usual Care
    • Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.

Arms, Groups and Cohorts

  • Experimental: Intervention Arm
    • Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
  • Active Comparator: Control Arm
    • Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.

Clinical Trial Outcome Measures

Primary Measures

  • Adherence
    • Time Frame: 12 weeks after study initiation or at therapy discontinuation, whichever is shorter
    • Defined as the number of adherent days divided by number of prescribed days. Adherent days will be calculated dichotomously based on whether a patient took all prescribed doses for the day within 2 hours of recommended time. Adherence data will be assessed via MEMS caps, which capture a date and time stamp each time the pill bottle is opened.

Secondary Measures

  • Persistence
    • Time Frame: 12 weeks after study initiation or at therapy discontinuation, whichever is shorter
    • Defined as the number of consecutive days on the regimen and conversely gaps in overall treatment, measured using MEMS caps.

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patient (age > 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib. – Patient possession of a mobile device that can send/receive SMS texts – Ability to respond to questions and engage with "Penny" in English – Ability to provide informed consent to participate in the study – Approval from the patient's medical oncologist to be approached Exclusion Criteria:

  • Inability to respond to questions and engage with "Penny" in English – Inability or unwillingness to provide informed consent to participate in the study – Inability to engage with SMS text-messaging platform – Concurrent enrollment in a therapeutic clinical trial – Taking more than one oral targeted therapy or concurrent chemotherapy during the study window – Lack of approval from the patient's oncologist

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Abramson Cancer Center at Penn Medicine
  • Collaborator
    • Lung Cancer Research Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Katharine Rendle, Assistant Professor – University of Pennsylvania
  • Overall Official(s)
    • Katharine A Rendle, PhD,MSW,MPH, Principal Investigator, University of Pennsylvania
    • Samuel U Takvorian, MD, MSHP, Principal Investigator, University of Pennsylvania

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.